Stella Osoba is the Senior Editor of trading and investing at Investopedia. She co-founded and chaired Women in Technical Analysis. She has 15+ years of experience as a financial writer and technical ...

One person that helped bring the chill was an analyst cutting his price target. Another two were executives at the biotech selling chunks of stock. The company was the target of an analyst price ...

Recursion Pharmaceuticals reported significant growth in sales and revenue for Q2 and the first half of 2025 but also experienced widening net losses. The release of their Boltz-2 model underscored a ...

Forbes contributors publish independent expert analyses and insights. I write about the business of healthcare. This article is more than 4 years old. Chris Gibson, Co-Founder & CEO, Recursion ...

Over the next few weeks, we expect a rally to ideally, and at least, 6560, from where a correction to 6335-6190 can materialize, followed by another rally to 6800. In our previous update from July 31 ...

We recently published 10 Stocks Crash as AI Glow Fades. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of Wednesday’s worst performers. Recursion Pharmaceuticals dropped for a third straight day ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Rallybio (RLYB) announced that it received an equity milestone payment of $12.5M from Recursion Pharmaceuticals (RXRX). The milestone payment was triggered by the initiation of additional preclinical ...